AR and prostate carcinoma: <h4>Background and objective</h4>The elucidation of prostate cancer biology and genomics has led to new therapies improving disease outcomes with novel androgen receptor (AR) pathway inhibitors (ARPIs), taxanes, and targeted therapeutics that require disease molecular stratification.<h4>Methods</h4>We are presenting a narrative and qualitative synthesis based on a systematic search.